Paul Foster

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up

Sylvia Adams, Jennifer R. Diamond, Erika Hamilton et al. · JAMA Oncology · 2018 · 278 citations · Full text

Crystal structure of the macrocycle-forming thioesterase domain of the erythromycin polyketide synthase: Versatility from a unique substrate channel

Shiou‐Chuan Tsai, Larry J. W. Miercke, J. Krucinski et al. · Proceedings of the National Academy of Sciences · 2001 · 210 citations · Full text

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors

Matthew D. Hellmann, T. W. Kim, Chul‐min Lee et al. · Annals of Oncology · 2019 · 188 citations · Full text

Phase Ib Study, Solid Tumors, Medicine +7

Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)

Brenton Flatt, Richard Martin, Tielin Wang et al. · Journal of Medicinal Chemistry · 2009 · 161 citations · Full text

Chronic Administration, Molecular Biology, Farnesoid X Receptor +19

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).

Johanna C. Bendell, Tae Won Kim, Boon Cher Goh et al. · Journal of Clinical Oncology · 2016 · 158 citations

Serial Biopsy Cohort, Immunology, Immunoediting +21